Target intelligence / Profile preview

Protein kinase cAMP-activated catalytic subunit alpha (PKA C-alpha)

Target
PKA C-alpha
Molecular classification
Enzyme, Serine/threonine protein kinase, AGC kinase family (Protein kinase A, G, and C)
01

Overview

Protein kinase cAMP-activated catalytic subunit alpha (PKA C-alpha) is the enzymatic component of protein kinase A responsible for phosphorylation of serine and threonine residues on target proteins, modulated by cellular levels of cyclic AMP (cAMP). Upon cAMP binding to the regulatory subunit, the catalytic subunit is released, becoming active. It plays essential roles in hormonal signaling pathways, energy metabolism, cell cycle regulation, memory formation, and many other cellular functions. Aberrant PKA C-alpha activity has been implicated in the pathogenesis of various cancers, cardiovascular conditions, and endocrine diseases, making it a validated therapeutic and research target[3][7][8][5].

Other names
Protein kinase A catalytic subunit alphacAMP-dependent protein kinase catalytic subunit alphaPKA catalytic subunit alphaPRKACA (gene/protein symbol)
02

Mechanism of action

Small molecules/drugs that elevate cAMP (e.g., beta-adrenergic agonists) indirectly activate PKA by increasing cAMP levels, leading to dissociation of the regulatory subunit and activation of the catalytic subunit[2][3][8].

03

Biological functions

Signal transductionRegulation of glucose metabolismRegulation of lipid metabolismCell cycle controlCell divisionContextual memoryPhosphorylation of proteins in diverse signaling pathways
04

Disease associations

CancerCardiovascular diseaseEndocrine disordersOther (implicated in disorders linked to defective phosphorylation)
05

Safety considerations

Off-target activation can result in widespread metabolic effects, including disturbance of glucose and lipid homeostasis[8][3].Sustained or aberrant activation is associated with tumorigenesis and cardiovascular risk[3][7].
06

Interacting drugs

No small molecule drugs directly target the catalytic subunit in a clinical setting; however, PKA is modulated indirectly by drugs or compounds affecting intracellular cAMP signaling (e.g., forskolin, phosphodiesterase inhibitors)

1 more in the full profile.

07

Biomarkers

Mutations or expression levels of PRKACA used as a biomarker in certain endocrine tumors (e.g., adrenal Cushing's syndrome)[7][3].

Beyond the preview

Go deeper on Protein kinase cAMP-activated catalytic subunit alpha (PKA C-alpha).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein kinase cAMP-activated catalytic subunit alpha (PKA C-alpha).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call